This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Astellas Announces Changes To Director Nominees For Election To OSI Pharmaceuticals' Board Of Directors

TOKYO, March 19 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503) today notified OSI Pharmaceuticals Inc. (Nasdaq: OSIP) that John D. Gilly, Ph.D. and Margaret T. Monaco will replace Jack Kaye and Heidi L. Steiger on the slate of directors Astellas plans to nominate for election to OSI Pharmaceutical's board of directors at OSI's 2010 annual stockholders' meeting.

Astellas is committed to providing an independent voice for OSI stockholders who want its board of directors to consider Astellas' compelling $52 per share all-cash offer for OSI.

Dr. Gilly currently serves as an Associate Director in the Biopharmaceutical Development Program with SAIC-Frederick, Inc., at NCI-Frederick, Inc., a federally funded research and development center focused on oncology.  Prior to joining SAIC-Frederick, Inc., he served as a director and Chief Operating Officer of Premier Research Group, plc, a U.K.-based publicly traded research organization that provides clinical trial services to biopharmaceutical and medical device companies, from 2006 through 2007, and as president of Premier Research Group's U.S. operations from 2002 through 2006.

Margaret T. Monaco is the Principal of Probus Advisors, a financial and strategic consulting firm.  She currently sits on the board and is a member of the audit committee of Barnes & Noble, Inc.  Ms. Monaco has also served as an independent director and member of the audit committee of W.P. Stewart & Co. Growth Fund, Inc. and is a former Chief Operating Officer of Merrill Lynch Ventures, LLC / KECALP Inc.

The highly qualified, full slate of independent directors proposed by Astellas is composed of Martin Edelshain, Cono R. Fusco, Michael A. Griffith, John D. Gilly, Jill Kanin-Lovers, Douglas E. Linton, Timothy P. Lynch, Jonathan R. Macey, Margaret T. Monaco and Joseph L. Turner.

Citigroup is acting as exclusive financial advisor to Astellas and Morrison & Foerster LLP is acting as legal counsel.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.37 -0.87%
FB $117.27 -0.67%
GOOG $701.43 0.82%
TSLA $212.10 -4.70%
YHOO $36.94 2.61%


Chart of I:DJI
DOW 17,660.71 +9.45 0.05%
S&P 500 2,050.63 -0.49 -0.02%
NASDAQ 4,717.0940 -8.5450 -0.18%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs